Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simethicone + N-acetyl cysteine is an oral combination of two agents used primarily as premedication to improve mucosal visibility during upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD). Simethicone acts as an anti-foaming agent by reducing surface tension of gas bubbles in the GI tract, thereby dispersing and preventing the formation of foam. N-acetyl cysteine (NAC) is a mucolytic that breaks down mucus by cleaving disulfide bonds in mucoproteins. The combination has been shown in multiple randomized controlled trials and meta-analyses to significantly improve mucosal visualization compared to placebo or either agent alone, reduce procedure time, and decrease the need for flushing during EGD. No significant adverse effects have been reported with this premedication regimen[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on simethicone + N-acetyl cysteine.